Published July 22, 2019 | Version v1
Dataset Open

Large-scale purification of Q23 and Q54 HTT from Sf9 and EXPI293F expression systems 2019/07/22

Creators

  • 1. Structural Genomics Consortium, University of Toronto

Description

Project: Biophysical investigation of purified HTT protein samples

Experiment: Large-scale purification of Q23 and Q54 HTT from Sf9 and EXPI293F expression systems

Date completed:­ 2019/07/22

Rationale: HTT samples are to be purified from different systems for subsequent biophysical and structural studies. 

Notes

Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.

Files

Large-scale purification of Q23 and Q54 HTT from Sf9 and EXPI293F expression systems 20190722.pdf

Files (917.7 kB)